Dapagliflozin Therapy In Cardiac Surgery

Sponsor
China National Center for Cardiovascular Diseases
Study ID
NCT05621551
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin — DRUG
    The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.

Study Details

This randomized controlled trial is to assess the effects of perioperative dapagliflozin on type 2 diabetic patients undergoing cardiac surgery

Key Dates

Start date
Nov 11, 2022
Status verified
Jul 2025
Primary completion
Jun 1, 2024
Completion
Jun 1, 2025

Study Design

Enrollment
178 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin
    Dapagliflozin 10 mg
  • No Intervention: Standard of care
    Standard care treatment of diabetes patients during perioperative cardiac surgery in our center

Primary Outcome Measure

Hs-Troponin-I [ Time Frame: within 2 days after surgery ]

Related Studies